Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma

Hai Wei Wu1†, Chao Liu1,2†, Xuan Wang3, Ling Zhang1, Weien Yuan4*, Jia Wei Zheng1*, Li Xin Su5 and Xin Dong Fan5

1 Department of Oral and Maxillofacial Surgery, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China, 3 Department of General Dentistry, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4 School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China, 5 Department of Interventional Therapy, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

The therapeutic options for infantile hemangiomas (IHs) have been greatly altered since the introduction of oral propranolol for successful treatments of IHs. Recently, there is an increase in the application of topical timolol maleate for treating superficial IHs. In the present study, we developed a new formulation of timolol maleate 0.5% hydrogel and treated 321 patients with superficial IHs to evaluate its efficacy and safety in the treatment of superficial IHs. This new timolol hydrogel was applied three times daily with a mean duration of 7.1 months. Response to treatment was assessed according to cosmetic improvement by using visual analog scale (VAS). The average VAS improvement after treatment was 76.4, with 126 patients (39.3%) achieving excellent responses, 159 patients (49.5%) achieving good responses, 33 patients (10.3%) achieving fair responses, and three patients (0.9%) achieving poor responses. Age at treatment initiation \((P = 0.0349)\) and lesion thickness \((P = 0.0147)\) were significantly associated with therapeutic efficacy. No severe side effects were observed in all patients. In conclusion, this new topical timolol maleate 0.5% hydrogel appears to be a proper candidate for treating superficial IHs, and our study provides supportive evidence and experience of topical timolol maleate in treating superficial IHs.

Keywords: infantile hemangioma, timolol maleate, hydrogel, topical therapy, drug safety

INTRODUCTION

Infantile hemangiomas (IHs) are the most frequently occurring pediatric lesions, which are benign vascular tumors with a characteristic growth pattern of rapid proliferation and slow regression over several years (1). Data from present publications indicates that decreasing gestational age, low birth weight, and a female predominance are closely associated with higher IH incidence (2). The decision on the initiation of IH treatment has been controversial in the past years due to the unique growth pattern of IHs. However, recent studies showed that most untreated IHs did not improve after 3.5 years of age (3), and more than 50% of untreated IHs exhibited significant residual lesions (4, 5). Thus, early and active intervention instead of “wait and see” policy might be a better strategy for the treatment of IHs.
The therapeutic options for IHs have been greatly altered since the introduction of oral propranolol for successful treatment of IHs. Numerous clinical studies have proved the efficacy and safety of propranolol treatment, which is now recommended as the first-line therapy in treating IHs (6). However, there is still controversy over the potential side effects of propranolol because propranolol could easily penetrate the blood–brain barrier and might affect the development of central nervous system (7). To avoid potential systemic side effects, topical beta blockers have been applied in the treatment of IHs, especially for superficial lesions. Significant progress for transdermal drug delivery has been made, including microneedle transdermal patch (8–11) and nano- transdermal drug delivery (12). In our previous study, topical application of nano-propranolol 0.5% hydrogel achieved good efficacy in treating uncomplicated superficial IHs (12). Recently, there is an increase in the application of topical timolol maleate for treating superficial IHs (13). However, clinical studies based on large samples are very limited, and no consensus exists about the use of topical timolol for treating IHs (13). In the present study, we treated superficial IHs with a new topical timolol maleate 0.5% hydrogel and aimed to evaluate the efficacy and safety in the treatment of superficial IHs in a large case series.

MATERIALS AND METHODS

Study Design
The study was conducted at Department of Oral and Maxillofacial Surgery, Shanghai Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. The study population was composed of 321 consecutive patients with superficial IHs who received treatment between June 2014 and June 2016. The study was carried out in accordance with Declaration of Helsinki. Informed consents were obtained from all parents of the patients and the study was approved by the Institute Review Board of Shanghai Ninth People’s Hospital. The exclusion criteria included hypersensitivity to timolol maleate, heart defects, or arrhythmia, a history with previous treatment, ulcerated, mucosal, or subcutaneous IHs, lesion thickness >10 mm and treatment duration less than 2 months.

Preparation of Novel Timolol Maleate 0.5% Hydrogel
Timolol maleate 0.5% hydrogel was prepared as follows: 16 g polyethylene glycol (PEG400, molecular weight: 400 Da), 5 g sodium benzoate, and 40 g glycerol dispersed in 200 ml purified water, and then 5 g timolol maleate was added into the well dispersed PVA hydrogel [32 g polyvinyl alcohol (PVA, molecular weight: 40,000 Da) and 32 g PVA (molecular weight: 100,000 Da)] dissolved in 670 ml purified water. The preparation of timolol maleate 0.5% hydrogel was stored in refrigerator at 4°C.

Treatment Regimen
Baseline screening was completed based on the criteria reported by Chan et al. (14), and all patients underwent a thorough physical examination prior to treatment, including cardiovascular examination, ultrasound investigation, and clinical photography. 321 patients met the inclusion criteria and were enrolled in the study. The hydrogel was applied three times daily, gently rubbed as a thin layer onto the whole surface of IH. During the first application of the hydrogel, cardiovascular examination (including heart rate and blood pressure) was performed before and after the treatment. Then cardiovascular examination was performed every 1 month as a routine. Consistent with our previous study (15), drug withdrawal criterion was based on clinical responses. Drug administration was continued until objective goals were obtained or no further improvement was achieved. The application of topical timolol was tapered by decreasing to twice a day for 2 weeks followed by once a day for 2 weeks, and then discontinued.

Outcome Measurement
The main goal of the treatment is to reduce cosmetic impairment caused by superficial lesions. Therefore, response to treatment was mainly assessed according to cosmetic improvement by using visual analog scale (VAS) (13, 16). The VAS score ranges from −100 (representing a doubling in the size and extent of the IH) to 100 (representing complete resolution), which was evaluated by another two independent physicians after reviewing all clinical photographs of IHs at baseline and after the full course of treatment. Therapeutic responses were graded as follows: excellent response (VAS score ranging from 90 to 100), good response (VAS score ranging from 50 to 90), fair response (VAS score ranging from 0 to 50), and poor response (VAS score ranging from −100 to 0). The follow-up period after the treatment ranged from 6 months to 1 year.

Evaluation of Skin Permeation of Topical Timolol Maleate 0.5% Hydrogel and Gel
To briefly evaluate the skin permeation of different formulations of topical timolol, UV detection was applied to compare the residual drug concentration after topical application of commercially available timolol maleate 0.5% gel (Timoptic-XE, Aton Pharma, Inc.) or this new timolol maleate 0.5% hydrogel. Six patients with superficial IHs (>2 cm²) were treated with both timolol maleate 0.5% gel and timolol maleate 0.5% hydrogel simultaneously. 2 ml gel or hydrogel was rubbed as a thin layer onto 1 cm² surface of IH in the same patient. All samples were collected at different time points (0, 4, 8, and 12 h after the treatment) and dissolved in 20 ml solution (ethanol: distilled water = 4:1) for detection of timolol maleate. The detector wavelength was adjusted to 296 nm according to the UV spectra of timolol (17) and optical density (OD) values of different groups were recorded. Permeation rate was calculated as follows: (OD values at 0 h − OD values at 4 h/8 h/12 h) × 100%/OD values at 0 h.

Statistical Methods
Analysis was performed using the SPSS software package (version 16.0; SPSS, Chicago, IL, USA). Descriptive data were expressed as numbers, percentages, or means ± SDs. Mann–Whitney U-test was used to compare the clinical responses at different groups. P-values <0.05 were considered as significant.
RESULTS

Clinical and Histological Features
The clinical characteristics of patients are listed in Table 1. Three hundred twenty-one patients were included in the study. The mean age at treatment initiation was 5.4 months, ranging from 2 to 21 months. There was a female predominance with a ratio of 2.7 to 1. The primary locations included head and neck region (58.9%), torso, and extremities (Table 1). Among all superficial IHs, there were 45.8% of lesions less than 1 mm in thickness and 54.2% more than 1 mm in thickness. Duration of topical timolol treatment ranged from 2 to 20 months, with a mean duration of 7.1 months.

Therapeutic Outcomes
The average VAS improvement after treatment was 76.4, with 126 patients (39.3%) achieving excellent responses, 159 patients (49.5%) achieving good responses, 33 patients (10.3%) achieving fair responses, and 3 patients (0.9%) achieving poor responses. Typical images with excellent responses are shown in Figures 1–3. Clinical responses demonstrated as blanching and softening of the lesions after treatment initiation. No patients experienced recurrence or rebound growth of the lesion at the last follow-up. Analysis of predictors of clinical responses is listed in Table 2, and clinical therapeutic differences in age at treatment initiation and duration of treatment is listed in Table 3. Age at treatment initiation \( (P = 0.0349) \) and lesion thickness \( (P = 0.0147) \) were associated with therapeutic efficacy. No significant VAS difference was observed in variables of gender, duration of treatment and lesion location.

Complications
No systemic adverse effects were noted during treatment. Local side effects were observed in six patients, with four patients experiencing pruritus and two patients experiencing excoriations.

Permeation Rate of Different Formulations of Topical Timolol Maleate
As shown in Table 4, permeation rate of novel topical timolol maleate 0.5% hydrogel was much higher than commercially available timolol maleate 0.5% gel 4, 8, and 12 h after administration.

DISCUSSION
Infantile hemangiomas are classified into superficial, deep, and compound types according to lesion distribution and anatomic depth of involvement (18). Oral propranolol has been the

---

TABLE 1 | Clinical characteristics of patients.

| Clinical characteristic | \( n (%) \) |
|-------------------------|-------------|
| Age                     |             |
| Mean age (months)       | 5.4         |
| Range (months)          | 2–21        |
| Gender                  |             |
| Male                    | 87 (27.1)   |
| Female                  | 234 (72.9)  |
| Lesion location         |             |
| Head and neck           | 189 (58.9)  |
| Body                    | 132 (41.1)  |
| Lesion thickness        |             |
| \( \leq 1 \) mm in thickness | 147 (45.8) |
| \( >1 \) mm in thickness | 174 (54.2)  |
| Duration of treatment   |             |
| Mean duration (months)  | 7.1         |
| Range (months)          | 2–20        |
TABLE 2 | Analysis of predictors of clinical response.

| Variables                | Mean VAS ± SD | Average duration of treatment (months) | P-value |
|--------------------------|---------------|----------------------------------------|---------|
| Gender                   |               |                                        |         |
| Male                     | 72.5 ± 25.6   | 7.4                                    | 0.3154  |
| Female                   | 72.8 ± 22.5   | 6.9                                    |         |
| Age at treatment initiation |             |                                        |         |
| ≤6 months                | 81.3 ± 16.7   | 7.6                                    | 0.0349* |
| >6 months                | 63.8 ± 32.2   | 5.9                                    |         |
| Duration of treatment    |               |                                        |         |
| ≤6 months                | 73.3 ± 26.4   | 4.3                                    | 0.3691  |
| >6 months                | 80.4 ± 18.3   | 10.9                                   |         |
| Lesion location          |               |                                        |         |
| Head and neck            | 72.3 ± 27.1   | 7.2                                    | 0.2487  |
| Body                     | 82.2 ± 15.5   | 6.8                                    |         |
| Lesion thickness         |               |                                        |         |
| ≤1 mm in thickness       | 81.7 ± 18.5   | 5.7                                    | 0.0147* |
| >1 mm in thickness       | 70.1 ± 27.0   | 8.6                                    |         |

*P < 0.05 was considered as significant.

TABLE 3 | Clinical therapeutic differences in age at treatment initiation and duration of treatment.

| Variables | Treatment responses |
|-----------|---------------------|
| Age       | Excellent | Good | Poor | Good | Poor |
| ≤6 months | 96        | 120  | 12   | 0    | 0    |
| >6 months | 30        | 99   | 21   | 3    |      |
| Duration  |           |      |      |      |      |
| ≤6 months | 72        | 81   | 19   | 2    |      |
| >6 months | 54        | 78   | 14   | 1    |      |

TABLE 4 | Permeation rate (%) of topical timolol maleate 0.5% hydrogel or gel.

| Samples        | Mean percentage ± SD at 4 h (%) | Mean percentage ± SD at 8 h (%) | Mean percentage ± SD at 12 h (%) |
|----------------|---------------------------------|---------------------------------|----------------------------------|
| Topical timolol maleate 0.5% hydrogel | 25.5 ± 9.4                      | 35.1 ± 7.2                      | 47.6 ± 9.4                      |
| Topical timolol maleate 0.5% gel      | 17.1 ± 8.0                      | 21.8 ± 10.5                     | 25.5 ± 11.0                     |

First-line treatment for high-risk and deep IH, and topical beta blocker therapy is recently attempted for the treatment of superficial IHs. Although topical beta blockers have been widely used for superficial IHs with acceptable effects, there is no consensus on the choice of beta blockers, optimal drug concentration, treatment frequency, and duration of treatment. In the present study, we applied a new timolol maleate 0.5% hydrogel three times daily with a mean duration of 7.1 months for the treatment of superficial IHs. Clinical efficacy was observed in all but three patients, and no one experienced severe systemic side effects. This study provided supportive evidence of the efficacy and safety of timolol in treating superficial IHs. Currently, topical drug therapy for superficial IHs has been prepared in several ways, including corticosteroids cream, imiquimod 5% cream, propranolol 0.5% hydrogel, propranolol 1% ointment, propranolol 2% ointment, propranolol 3% hydrogel, timolol 0.1% gel, timolol 0.25% gel forming solution, timolol 0.5% eye drop, timolol 0.5% gel forming solution, and timolol 0.5% gel and so on (19). In the present study, we developed a new formulation of timolol maleate 0.5% hydrogel. Timolol maleate was incorporated into PEG/PVA hydrogel, which has become candidate nano materials for controlled drug delivery (20). UV detection of timolol maleate demonstrated that this novel hydrogel could permeate skin more easily than commercially available timolol maleate 0.5% gel with the help of PEG/PVA hydrogel system, suggesting higher bioavailability and better drug percutaneous absorption of the new hydrogel. The hydrogel can keep skin moist and coating, which could reduce cutaneous stimulus of the topical drug and incidence of side effects. Compared with timolol eye drop and gel forming solution, the hydrogel was more convenient to apply in infants because solutions were easily flowing while the hydrogel would immediately become a thin layer of gel after application.

Few clinical studies were implemented to compare the efficacy and safety of different drugs. In a retrospective study by Qiu et al., timolol 0.5% eye drop and imiquimod 5% cream achieved equivalent clinical efficacy, but fewer side effects were observed in patients treating with topical timolol (16). Danarti et al. compared the effectiveness of topical corticosteroids and timolol maleate 0.5% solution or gel (21). Effectiveness of topical timolol maleate 0.5% solution or gel was significantly better than topical corticosteroids, but there was no difference in IHs treating with timolol solution versus gel (21). A cohort study showed that timolol 0.5% gel forming solution was more effective than timolol 0.1% gel forming solution, suggesting that drug concentration is an important predictor for clinical responses (22). Drug frequencies also vary from twice daily to five times daily mostly based on the clinical experience of physicians (23). In our opinion, higher frequency is often associated with better efficacy but higher risk of side effects and inconvenience of administration, and three times daily is preferable for the application of timolol maleate 0.5% gel or solution. Satisfactory efficacy of this new topical timolol maleate 0.5% hydrogel is achieved, with an average VAS improvement of 76.4. Clinical responses were observed in 318 patients, and only three patients responded poorly but without further development. Currently, several clinical studies based on large sample size have been implemented. One retrospective, cohort study containing 73 patients reported that a mean improvement of 45% was observed in their study (22). The largest retrospective study to date reported over 20% with poor response demonstrated by VAS-SEV after 6–9 months of timolol therapy (13). Compared with these results, it seems that the response rate in our study is higher than other reported studies of topical timolol treatment based on large sample size, suggesting that this new formulation of timolol maleate 0.5% hydrogel might favor in improving the clinical effects.

Infantile hemangiomas have a typical growth pattern with the rapid proliferation during 5–9 postnatal months and slow regression after the first year (2). Recent studies indicate that age at treatment initiation is an important predictor of clinical responses. A retrospective study showed that better therapeutic
responses were observed in patients who initiated treatments in the first 3 months (24). A prospective study by Yu et al. suggested that a higher regression rate was achieved in patients younger than 6 months old who received 4 months of topical timolol treatment (25). Our results demonstrated that higher VAS improvement was observed in groups of age ≤6 months at the start of treatment, which is consistent with previous studies. This is probably because of better inhibitory effect of beta adrenergic blockers in proliferating hemangioma cells than involving hemangioma cells. It has been demonstrated that beta adrenergic blockers could induce vasoconstriction, endothelial cell apoptosis, and inhibition of angiogenesis through beta adrenergic signaling pathway and VEGF signaling pathway (26). Moreover, positive expression of beta adrenergic receptor-2 and VEGFR-2 has been detected in proliferating hemangioma while weakly positive expression in involuting hemangioma (26). In our opinion, the therapeutic effects of timolol at different age initiations is closely associated with the expression of beta adrenergic receptor and VEGFR at different stages, which might explain for better clinical responses during the first 1–6 months. Lesion thickness is also closely associated with clinical responses. In the study by Puttgen et al., better clinical responses were obtained in IHs < 1 mm thickness compared with IHs > 1 mm thickness (13). In our study, VAS score was significantly higher in IHs < 1 mm thick than in IHs > 1 mm thick (P = 0.0147). However, it should be noted that there were no significant differences in duration of treatment between ≤6 months and >6 months in the study. According to our clinical experience, it seemed that obvious clinical responses of this new topical timolol maleate 0.5% hydrogel were observed during the first 1–6 months, and subsequent improvement varied between individuals. Further well-designed prospective study should be implemented to analyze the effect of different stages of initiating topical timolol treatment on clinical responses.

Timolol is eight times as potent as propranolol by intravenous administration (27). For safety consideration, topical timolol is not suggested for treating ulcerated and mucosal IHs because of high permeability through the lesions. Compared with oral propranolol, decreased side effect is one distinct advantage of topical timolol in treating IHs. In the present study, no systemic side effects were recorded and rate of local side effect was 2% (6/321), which indicated high safety of topical timolol maleate treatment.

Among six patients experiencing local side effects, four patients had pruritus after a mean duration of 1 month, manifesting as scratching the lesion after application of the hydrogel. The two patients had excoriations, but no further ulceration. All these local side effects were not significant enough to discontinue the therapy.

In conclusion, this new topical timolol maleate 0.5% hydrogel appears to be a proper candidate for treating superficial IHs with satisfactory clinical responses and mild side effects in this series. Our study provides supportive evidence and experience of topical timolol maleate in treating superficial IHs.

ETHICS STATEMENT

The study was conducted at Department of Oral and Maxillofacial Surgery, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. The study was carried out in accordance with Declaration of Helsinki. Informed consents were obtained from all parents of the patients and the study was approved by the Institute Review Board of Shanghai Ninth People’s Hospital.

AUTHOR CONTRIBUTIONS

HW, CL, XW, LZ, WY, JZ, LS, and XF participated in its design, searched databases, extracted and assessed studies, and helped to draft the manuscript. HW and CL wrote the manuscript. WY and JZ conceived the initial idea and the conceptualization, participated in the data extraction and analysis, and revised the manuscript. All authors read and approved the final manuscript.

FUNDING

This study is financially supported by the grants of National Natural Science Foundation of China (No. 81570992 and 81470755), Funds for Interdisciplinary Projects of Medicine and Engineering by Shanghai Jiao Tong University (No. YG2015MS06 and YG2014QN06), and the Technology Development Plan Project of Shandong Province, China (No. 2014GSF118164). We also appreciate the generous help from faculties of Instrumental Analysis Centre (IAC) of Shanghai Jiao Tong University.

REFERENCES

1. Zheng JW, Zhang L, Zhou Q, Mai HM, Wang YA, Fan XD, et al. A practical guide to treatment of infantile hemangiomas of the head and neck. Int J Clin Exp Med (2013) 6:851–60.
2. Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed (2015) 100:F85–91. doi:10.1136/archdischild-2014-306197
3. Couto RA, Macellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg (2012) 130:619–24. doi:10.1097/PRS.0b013e31825dc129
4. Bauland CG, Luning TH, Smit JM, Zeebregts CJ, Spauwen PH. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg (2011) 127:1643–8. doi:10.1097/01.PRS.0b013e31820bd2ac
5. Baselga E, Ree E, Coulie J, Munoz FZ, Boon LM, McCuaig C, et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol (2016) 152:1239–43. doi:10.1001/jamadermatol.2016.2905
6. Leaute-Labreze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posinuas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med (2015) 372:735–46. doi:10.1056/NEJMoa1404710
7. Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol (2015) 172:13–23. doi:10.1111/bjd.13379
8. Chen W, Li H, Shi D, Liu Z, Yuan W. Microneedles as a delivery system for gene therapy. Front Pharmacol (2016) 7:137. doi:10.3389/fphar.2016.00137
9. Hong X, Wei L, Wu F, Wu Z, Chen L, Liu Z, et al. Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine. Drug Des Devel Ther (2013) 7:945–52. doi:10.2147/DDDT.S44401
10. Yang S, Feng Y, Zhang L, Chen N, Yuan W, Jin T. A scalable fabrication process of polymer microneedles. Int J Nanomedicine (2012) 7:1415–22. doi:10.2147/IJNN.S48511
11. Hong X, Wu Z, Chen L, Wu F, Wei L, Yuan W. Hydrogel microneedle arrays for transdermal drug delivery. Nano-Micro Lett (2014) 6(3):191–9. doi:10.3389/fphar.2014.00137
12. Chen ZG, Zheng JW, Yuan ML, Zhang L, Yuan WE. A novel topical nano-propranolol for treatment of infantile hemangiomas. *Nanomedicine* (2015) 11:1109–15. doi:10.1016/j.nano.2015.02.015

13. Puttgen K, Lucky A, Adams D, Pope E, McCuaig C, Powell J, et al. Topical timolol maleate treatment of infantile hemangiomas. *Pediatrics* (2016) 138:e20160355. doi:10.1542/peds.2016-0355

14. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. *Pediatrics* (2013) 131:e1739–47. doi:10.1542/peds.2012-3828

15. Ge J, Zheng J, Zhang L, Yuan W, Zhao H. Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. *Sci Rep* (2016) 6:19765. doi:10.1038/srep19765

16. Qiu Y, Ma G, Yang J, Hu X, Chen H, Jin Y, et al. Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study. *Clin Exp Dermatol* (2013) 38:845–50. doi:10.1111/ced.12150

17. Merino-Bohórquez V, Casas M, Caracuel F, Cameán M, Fernández-Anguita MJ, Ramírez-Soto G, et al. Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma. *Pharm Dev Technol* (2015) 20:562–9. doi:10.3109/10837450.2014.898657

18. Puttgen KB. Diagnosis and management of infantile hemangiomas. *Pediatr Clin North Am* (2014) 61:383–402. doi:10.1016/j.pcl.2013.11.010

19. Painter SL, Hildebrand GD. Review of topical beta blockers as treatment for infantile hemangiomas. *Surv Ophthalmol* (2016) 61:51–8. doi:10.1016/j.survophthal.2015.08.006

20. Wan T, Stylios GK, Giannoudi M, Giannoudis PV. Investigating a new drug delivery nano composite membrane system based on PVA/PCL and PVA/HA (PEG) for the controlled release of biopharmaceuticals for bone infections. *Injury* (2015) 46:S39–43. doi:10.1016/S0020-1383(15)30053-X

21. Danarti R, Ariwibowo L, Radjono S, Budiyanto A. Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids – a single-center experience of 278 cases. *Dermatology* (2016) 232:566–71. doi:10.1159/000448396

22. Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried E, Lara-Corrales I, Lam J, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. *Pediatr Dermatol* (2012) 29:28–31. doi:10.1111/j.1523-1470.2011.01664.x

23. Ovadia SA, Landy DC, Cohen ER, Yang EY, Thaller SR. Local administration of beta-blockers for infantile hemangiomas: a systematic review and meta-analysis. *Ann Plast Surg* (2015) 74:256–62. doi:10.1097/SAP.0000000000000390

24. Xu G, Lv R, Zhao Z, Huo R. Topical propranolol for treatment of superficial infantile hemangiomas. *J Am Acad Dermatol* (2012) 67:1210–3. doi:10.1016/j.jaad.2012.03.009

25. Yu L, Li S, Su B, Liu Z, Fang J, Zhu L, et al. Treatment of superficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants. *Exp Ther Med* (2013) 6:388–90. doi:10.3892/etm.2013.1176

26. Kum YJ, Khan ZA. Mechanisms of propranolol action in infantile hemangioma. *Dermatoendocrinol* (2014) 6:e979699. doi:10.4161/19381980.2014.979699

27. Singh BN, Williams FM, Whitlock RM, Collett J, Chew C. Plasma timolol levels and systolic time intervals. *Clin Pharmacol Ther* (1980) 28:159–66. doi:10.1038/clpt.1980.145

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewers, XD and WL, and handling editor declared their shared affiliation, and the handling editor states that the process nevertheless met the standards of a fair and objective review.

**Copyright © 2017 Wu, Liu, Wang, Zhang, Yuan, Zheng, Su and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**